1. Association of serum neurofilament light and disease severity in patients with spinocerebellar ataxia type 3
- Author
-
Weihua Liao, Jingyi Tang, Yuting Shi, Peng Huirong, Youming Zhang, Xue-wei Zhang, Qiyong Cai, Chunrong Wang, Puzhi Wang, Thomas Klockgether, Hong Jiang, Jennifer Zhang, Shaohui Liu, Linlin Wan, Tianjiao Li, Yun Peng, Na Wan, Chen Zhao, Yue Xie, Hongyu Yuan, Beisha Tang, and Rong Qiu
- Subjects
Male ,0301 basic medicine ,blood [Neurofilament Proteins] ,Severity of Illness Index ,Gastroenterology ,blood [Machado-Joseph Disease] ,physiopathology [Machado-Joseph Disease] ,0302 clinical medicine ,pathology [Gray Matter] ,Neurofilament Proteins ,Interquartile range ,pathology [White Matter] ,Gray Matter ,Young adult ,Ataxin-3 ,blood [Biomarkers] ,medicine.diagnostic_test ,Machado-Joseph Disease ,Middle Aged ,Magnetic Resonance Imaging ,White Matter ,medicine.anatomical_structure ,pathology [Machado-Joseph Disease] ,Spinocerebellar ataxia ,Female ,medicine.symptom ,Adult ,Heterozygote ,medicine.medical_specialty ,Ataxia ,Asymptomatic ,diagnostic imaging [White Matter] ,White matter ,Young Adult ,03 medical and health sciences ,genetics [Ataxin-3] ,Internal medicine ,Severity of illness ,medicine ,Humans ,ddc:610 ,neurofilament protein L ,business.industry ,diagnostic imaging [Gray Matter] ,ATXN3 protein, human ,Magnetic resonance imaging ,medicine.disease ,diagnosis [Machado-Joseph Disease] ,Repressor Proteins ,genetics [Repressor Proteins] ,Cross-Sectional Studies ,030104 developmental biology ,Mutation ,Neurology (clinical) ,business ,Biomarkers ,030217 neurology & neurosurgery - Abstract
ObjectiveTo investigate serum neurofilament light protein (sNfL) levels in patients with spinocerebellar ataxia type 3 (SCA3) and to determine whether they are associated with disease severity.MethodsThis cross-sectional study enrolled 185 healthy controls and 235 ATXN3 mutation carriers (17 asymptomatic stage, 20 preclinical stage, and 198 ataxic stage). We measured sNfL levels with the single molecule array (Simoa) platform. Clinical disease severity was assessed using the Scale of Assessment and Rating of Ataxia (SARA) and the Inventory of Nonataxia Signs (INAS). In a subgroup of 50 ataxic stage patients, we further evaluated the gray matter volume and the integrity of white matter fibers by MRI.ResultssNfL concentrations were elevated in asymptomatic, preclinical, and ataxic ATXN3 mutation carriers compared to controls (12.18 [10.20–13.92], 21.84 [18.37–23.45], 36.06 [30.04–45.90], and 8.24 [5.92–10.84] pg/mL, median [interquartile range], respectively, p < 0.001). sNfL correlated with SARA (r = 0.406, 95% confidence interval [CI] 0.284–0.515, p < 0.0001) and INAS (r = 0.375, 95% CI 0.250–0.487, p < 0.0001), and remained significant after adjustment for age and CAG repeats. In addition, we observed negative correlations of the sNfL with gray matter volume in the left precentral gyrus and the left paracentral lobule as well as with the mean diffusivity in widespread white matter tracts.ConclusionOur results demonstrate that sNfL levels are increased in SCA3 and are associated with clinical disease severity, which supports sNfL as a biomarker for disease severity in SCA3.Classification of evidenceThis study provides Class II evidence that in patients with SCA3, sNfL elevations are associated with clinical disease severity.
- Published
- 2020
- Full Text
- View/download PDF